3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
8
Carcinoma, Renal Cell
6
Urinary Bladder Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Carcinoma, Non-Small-Cell Lung
3
Wilms Tumor
2
Squamous Cell Carcinoma of Head and Neck
2
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neuroblastoma
2
Neoplasms
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Hairy Cell
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Interventions
pembrolizumab
31
Nivolumab
12
Cyclophosphamide
10
fludarabine
9
aldesleukin
8
atezolizumab
7
durvalumab
6
Magnetic Resonance Spectroscopy
6
Trastuzumab
5
Specimen Handling
5
Paclitaxel
5
Ipilimumab
5
Docetaxel
5
Biopsy
5
fludarabine phosphate
4
Radiotherapy
4
Interleukin-2
4
Gene Expression Profiling
4
Carboplatin
4
tisotumab vedotin
3
cemiplimab
3
aflibercept
3
Polymerase Chain Reaction
3
Immunoglobulin G
3
Early Intervention, Educational
3
Cisplatin
3
Bevacizumab
3
tremelimumab
2
tislelizumab
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Vorinostat
×
Genitourinary
×
Clear all
NCT04357873
2025-02-19
PEVOsq
UNICANCER
Phase 2
Completed
112 enrolled